Sei Investments Co. Has $5.99 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Sei Investments Co. reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 38.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 494,444 shares of the company's stock after selling 312,976 shares during the quarter. Sei Investments Co. owned approximately 0.10% of Elanco Animal Health worth $5,988,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Bank of Montreal Can lifted its stake in Elanco Animal Health by 3.5% in the 3rd quarter. Bank of Montreal Can now owns 416,336 shares of the company's stock worth $5,962,000 after purchasing an additional 14,190 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Elanco Animal Health by 2,453.2% during the third quarter. BNP Paribas Financial Markets now owns 260,325 shares of the company's stock valued at $3,824,000 after buying an additional 250,129 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Elanco Animal Health by 1.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 107,683 shares of the company's stock valued at $1,582,000 after purchasing an additional 2,051 shares during the period. Edgestream Partners L.P. bought a new position in Elanco Animal Health in the third quarter worth about $925,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Elanco Animal Health in the third quarter worth $281,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Down 5.7 %

Shares of ELAN traded down $0.56 during midday trading on Friday, hitting $9.17. 9,132,532 shares of the stock were exchanged, compared to its average volume of 4,829,741. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market cap of $4.55 billion, a P/E ratio of 22.91, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 52-week low of $8.80 and a 52-week high of $18.80. The stock has a fifty day simple moving average of $11.04 and a 200 day simple moving average of $12.27.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 earnings per share. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on ELAN shares. Piper Sandler reduced their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Stifel Nicolaus cut their price objective on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a report on Friday, February 21st. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Finally, Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $15.17.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares of the company's stock, valued at $1,105,903.10. The trade was a 10.93 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.